HEALTH TECHNOLOGY ASSESSMENT
VOLUME 21 ISSUE 9 MARCH 2017
ISSN 1366-5278
DOI 10.3310/hta21090
Oral anticoagulants for primary prevention, treatment
and secondary prevention of venous thromboembolic
disease, and for prevention of stroke in atrial
fibrillation: systematic review, network
meta-analysis and cost-effectiveness analysis
Jonathan AC Sterne, Pritesh N Bodalia, Peter A Bryden, Philippa A Davies,
Jose A López-López, George N Okoli, Howard HZ Thom,
Deborah M Caldwell, Sofia Dias, Diane Eaton, Julian PT Higgins,
Will Hollingworth, Chris Salisbury, Jelena Savovic´, Reecha Sofat,
Annya Stephens-Boal, Nicky J Welton and Aroon D Hingorani
Oral anticoagulants for primary
prevention, treatment and secondary
prevention of venous thromboembolic
disease, and for prevention of stroke in
atrial fibrillation: systematic review,
network meta-analysis and
cost-effectiveness analysis
Jonathan AC Sterne,
1
* Pritesh N Bodalia,
2,3
Peter A Bryden,
1
Philippa A Davies,
1
Jose A López-López,
1
George N Okoli,
1
Howard HZ Thom,
1
Deborah M Caldwell,
1
Sofia Dias,
1
Diane Eaton,
4
Julian PT Higgins,
1
Will Hollingworth,
1
Chris Salisbury,
1
Jelena Savovic
´
,
1
Reecha Sofat,
5,6
Annya Stephens-Boal,
7
Nicky J Welton
1
and Aroon D Hingorani
5,6
1
School of Social and Community Medicine, University of Bristol, Bristol, UK
2
University College London Hospitals, NHS, London, UK
3
Royal National Orthopaedic Hospital, NHS, London, UK
4
AntiCoagulation Europe, Bromley, UK
5
University College London, London, UK
6
London School of Hygiene and Tropical Medicine, London, UK
7
Thrombosis UK, Llanwrda, UK
*Corresponding author
Declared competing interests of authors: Jonathan AC Sterne was a National Institute for Health
Research (NIHR) Health Technology Assessment Clinical Trial Board member from 2010 to 2014 and is a
NIHR Senior Investigator (award NF-SI-0611-10168). Chris Salisbury is a NIHR Health Services and Delivery
Research Board member, and also reports receipt of a research grant from NIHR. Howard HZ Thom reports
personal fees for consultancy work from Novartis Pharma, Eli Lilly and company, and ICON Plc, all outside
this work. Sofia Dias reports grants from NIHR, Novartis and Pfizer, all outside this work. Diane Eaton
reports other from Boehringer Ingelheim, Pfizer, Bayer, Leo Pharmaceuticals and Bristol-Myers Squib,
outside the submitted work, and AntiCoagulation Europe (ACE), a registered charity, the aims of which
include raising awareness of the risk and prevention of thrombosis, and providing information, education
and support to people who are on anticoagulation therapy for any duration, including long term for those
with chronic conditions. Diane Eaton works with ACE in an associate consultant capacity in the role of
Project Development Manager. She has over 40 years of personal experience of anticoagulation therapy
and represents ACE as a patient expert at the National Institute for Health and Care Excellence (NICE).
On behalf of the charity, she has provided the patient perspective for the submissions for the technology
appraisals for the novel oral anticoagulants (NOACs) and Diagnostic Guidance for Coagulometers over a
4-year period. Please note that the financial information has been prepared by Eve Knight, Chief Executive
of AntiCoagulation Europe, for the purpose of inclusion in this document.
Published March 2017
DOI: 10.3310/hta21090
This report should be referenced as follows:
Sterne JAC, Bodalia PN, Bryden PA, Davies PA, López-López JA, Okoli GN, et al. Oral
anticoagulants for primary prevention, treatment and secondary prevention of venous
thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review,
network meta-analysis and cost-effectiveness analysis. Health Technol Assess 2017;21(9).
Health Technology Assessment is indexed and abstracted in Index Medicus/MEDLINE, Excerpta
Medica/EMBASE, Science Citation Index Expanded (SciSearch
®
) and Current Contents
®
/
Clinical Medicine.